GL Pharm Tech Corporation registers Phase 3 trial of W2505 for erectile dysfunction
The study, first posted on ClinicalTrials.gov on October 5, 2026, plans to enroll 228 participants and begin in September 2026. It is a prospective, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of W2505.
Primary source
ClinicalTrials.gov registry record, October 5, 2026
The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505.
Read the source: The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505. clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation